newsfilter
← Earnings
Earnings Releases·

Sagimet Biosciences — Third Quarter 2026 Earnings Summary

  • Q3 2026 net loss was $19.1 million (vs. $12.9 million in Q3 2025) and $43.8 million for the nine months ended September 30, 2026 (vs. $41.5 million in 2025); R&D expenses rose to $16.3 million for the quarter (vs. $9.7 million) and $34.9 million year-to-date (vs. $32.3 million).
  • Total assets and stockholders' equity increased to $282.1 million and $242.2 million respectively as of September 30, 2026, driven by a $115 million gross proceeds equity offering completed in October 2026, bringing pro forma cash and investments to approximately $356 million.
  • Pro forma capital is sufficient to fund operations through mid-2029, covering the U.S. AURORA Phase 3 trial readout in H2 2027 and potential NDA submission; the Phase 3 trial for denifanstat in the U.S. began dosing in October 2026.
  • Positive Phase 3 data from license partner Ascletis in China demonstrated sustained efficacy through 52 weeks, while the Phase 2 trial for TVB-3567 in moderate to severe acne is anticipated to initiate before the end of 2026.
Company
SAGIMET BIOSCIENCES INC
Sector
Healthcare
Industry
Biotechnology